aTyr Pharma’s Phase 3 Study on Efzofitimod Moves Forward with Positive Safety Review

aTyr Pharma has received encouraging news regarding its Phase 3 EFZO-FIT™ study, which is evaluating efzofitimod as a potential treatment for pulmonary sarcoidosis. An independent data and safety monitoring board (DSMB) conducted its fourth pre-planned safety review and found no concerns, recommending that the study continue as planned. This milestone strengthens confidence in efzofitimod’s safety profile, especially as a potential long-term alternative to corticosteroids, which are commonly used to manage sarcoidosis but can have significant side effects.

The EFZO-FIT™ trial is a 52-week, placebo-controlled study involving 268 patients across multiple countries, testing two different doses of efzofitimod. The study’s primary goal is to assess its ability to reduce reliance on corticosteroids, while also monitoring lung function and symptom relief. “This latest safety review reinforces our belief in efzofitimod’s potential to improve treatment options for pulmonary sarcoidosis patients,” said Sanjay S. Shukla, M.D., M.S., President and CEO of aTyr Pharma. The company expects to share topline results in the third quarter of this year.